{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:49:36Z","timestamp":1761806976693},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1016\/j.curtheres.2003.09.002","type":"journal-article","created":{"date-parts":[[2003,11,8]],"date-time":"2003-11-08T12:12:47Z","timestamp":1068293567000},"page":"522-537","source":"Crossref","is-referenced-by-count":14,"title":["Effects of policosanol on borderline to mildly elevated serum total cholesterol levels: a prospective, double-blind, placebo-controlled, parallel-group, comparative study"],"prefix":"10.1016","volume":"64","author":[{"given":"Gladys","family":"Casta\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"M\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Illnait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meylin","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2003.09.002_BIB1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.CIR.83.1.356","article-title":"An updated coronary risk profile. A statement for health professionals","volume":"83","author":"Anderson","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB4","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB9","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"Suppl A","key":"10.1016\/j.curtheres.2003.09.002_BIB10","first-page":"A12","article-title":"European and American recommendations for coronary heart disease prevention","volume":"19","author":"Wood","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB11","series-title":"The ILIB Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease","author":"Gotto","year":"2000"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB12","first-page":"366","article-title":"A review of clinical trials comparing HMG-CoA reductase inhibitors","volume":"16","author":"Illingworth","year":"1994","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/01.CIR.97.15.1436","article-title":"Statin trials and goals of cholesterol-lowering therapy","volume":"97","author":"Grundy","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/106002809502907-818","article-title":"Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia","volume":"29","author":"Hsu","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB15","first-page":"258","article-title":"Statin myopathies: Pathophysiologic and clinical perspectives","volume":"24","author":"Baker","year":"2001","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1358\/dof.2000.025.06.574693","article-title":"Policosanol","volume":"25","author":"M\u00e1s","year":"2000","journal-title":"Drugs of the Future"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB17","first-page":"27","article-title":"Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment","volume":"14","author":"Pons","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB18","first-page":"159","article-title":"A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia","volume":"15","author":"Canetti","year":"1995","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0011-393X(97)80052-5","article-title":"A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia","volume":"58","author":"Benitez","year":"1997","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0009-9236(99)70139-6","article-title":"Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors","volume":"65","author":"M\u00e1s","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/09513590009167681","article-title":"Effect of policosanol on postmenopausal women with type II hypercholesterolemia","volume":"14","author":"Casta\u00f1o","year":"2000","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB22","first-page":"105","article-title":"Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients","volume":"19","author":"Casta\u00f1o","year":"1999","journal-title":"Int J Clin Pharm Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB23","doi-asserted-by":"crossref","first-page":"M186","DOI":"10.1093\/gerona\/56.3.M186","article-title":"Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk","volume":"56","author":"Casta\u00f1o","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00044011-200121020-00003","article-title":"Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women","volume":"21","author":"Fern\u00e1ndez","year":"2001","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00044011-200121070-00004","article-title":"Effects of policosanol in older hypercholesterolemic patients with coronary disease","volume":"21","author":"M\u00e1s","year":"2001","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2337\/diacare.18.3.393","article-title":"Treatment of hypercholesterolemia in NIDDM with policosanol","volume":"18","author":"Torres","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB27","first-page":"117","article-title":"Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus","volume":"19","author":"Crespo","year":"1999","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB28","first-page":"199","article-title":"Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts","volume":"27","author":"Men\u00e9ndez","year":"1994","journal-title":"Biol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1079\/BJN19970090","article-title":"Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet","volume":"77","author":"Men\u00e9ndez","year":"1996","journal-title":"Br J Nutr"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0188-4409(00)00265-4","article-title":"Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts","volume":"32","author":"Men\u00e9ndez","year":"2001","journal-title":"Arch Med Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0011-393X(98)85030-3","article-title":"Policosanol: Results of a postmarketing surveillance study of 27,879 patients","volume":"59","author":"Fern\u00e1ndez","year":"1998","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0011-393X(99)80024-1","article-title":"Pharmacoepidemiologic study of policosanol","volume":"60","author":"M\u00e1s","year":"1999","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0002-9343(97)89459-4","article-title":"Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals","volume":"100","author":"Schectman","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/clinchem\/27.6.838","article-title":"Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride","volume":"27","author":"Seigler","year":"1981","journal-title":"Clin Chem"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-199917030-00003","article-title":"Cost of treating to a modified European Atheroesclerosis Society LDL-C Target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin","volume":"17","author":"Smith","year":"1999","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0049-3848(93)90030-R","article-title":"Effects of Policosanol on platelet aggregation in rats","volume":"69","author":"Arruzazabala","year":"1993","journal-title":"Thromb Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0952-3278(93)90080-G","article-title":"Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2","volume":"49","author":"Arruzazabala","year":"1993","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB39","first-page":"67","article-title":"Effect of policosanol on platelet aggregation in healthy volunteers","volume":"16","author":"Valdes","year":"1996","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1006\/phrs.1996.0086","article-title":"Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers","volume":"34","author":"Arruzazabala","year":"1996","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/phrs.1997.0201","article-title":"Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers","volume":"36","author":"Arruzazabala","year":"1997","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/phrs.1998.0324","article-title":"Interaction policosanol-warfarin on bleeding time and thrombosis in rats","volume":"38","author":"Carbajal","year":"1998","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB43","first-page":"119","article-title":"Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients","volume":"20","author":"Arruzazabala","year":"1998","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB44","doi-asserted-by":"crossref","DOI":"10.2165\/00044011-200323100-00003","article-title":"Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidemia and type 2 diabetes mellitus","author":"Casta\u00f1o","year":"2003","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2125.2000.00250.x","article-title":"Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro","volume":"50","author":"Men\u00e9ndez","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0011-393X(00)88013-3","article-title":"Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: A randomized, double-blind pilot study","volume":"61","author":"Men\u00e9ndez","year":"2000","journal-title":"Curr Ther Res Clin Exp"},{"issue":"Suppl B","key":"10.1016\/j.curtheres.2003.09.002_BIB47","first-page":"Number 9","article-title":"Effects of policosanol (5\u201310 mg\/day) in older hypercholesterolemic patients","volume":"39","author":"M\u00e1s","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2003.09.002_BIB48","first-page":"21","article-title":"Effect of policosanol on arterial blood pressure in rats. Study of the pharmacological interaction with nifedipine and propranolol","volume":"29","author":"Molina Cuevas","year":"1998","journal-title":"Arch Med Res"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X03001607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X03001607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T17:42:40Z","timestamp":1585244560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X03001607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["S0011393X03001607"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2003.09.002","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}